LOTTE BIOLOGICS Forms Contract Manufacturing Alliance with Prominent U.S. Biopharmaceutical Firm

LOTTE BIOLOGICS Secures New Partnership

• New Contract Announcement: LOTTE BIOLOGICS has entered a late-stage to commercial contract manufacturing partnership with a U.S.-based biopharmaceutical company, focusing on a Phase 3 program that may expand into new therapeutic areas pending regulatory approvals. The contract is set to last until mid-2030.

• Strategic Importance: This partnership emphasizes LOTTE BIOLOGICS' manufacturing capabilities and quality leadership in the global market, particularly highlighting the advantages of its U.S. manufacturing operations.

Growth and Industry Trends

• Third Major Partnership in 2025: This contract marks the third significant partnership secured by LOTTE BIOLOGICS in 2025, reflecting the company's alignment with the industry's trend towards reshoring and supply chain realignment in U.S. biomanufacturing.

• Dual-Site Operations: The company operates dual sites in Syracuse, NY, and Songdo, Korea, under a unified quality system, which enhances collaboration with U.S. firms and expands its global client base by providing reliable supply and flexibility to meet dynamic demands.

Client Confidence and Future Prospects

• Client Trust: A representative from LOTTE BIOLOGICS stated that this partnership showcases strong client confidence in their global network and technical expertise, reinforcing their commitment to support the partner's indication expansion strategy.

• Commitment to Innovation: LOTTE BIOLOGICS aims to accelerate the availability of innovative therapies for patients worldwide, leveraging its dual-site reliability and significant conjugation capacities in the U.S. to ensure dependable delivery of advanced medical solutions.